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Abstract. Breast cancer encompasses a heterogeneous group 
of diseases at the molecular level. It is known that chemo-
sensitivity of breast cancer depends on its molecular subtype. 
We investigated the growth inhibitory effect of valproic 
acid (VPA), a histone deacetylase (HDAC) inhibitor, and 
the mechanism of this inhibition on four breast cancer cell 
lines with different molecular subtypes. The growth inhibi-
tory effect of VPA in the four different breast cancer cell 
lines was investigated. The alteration of levels of p21 WAF1, 
cleaved caspase-3, acetylated Heat shock protein (Hsp) 90, 
acetylated Hsp70, and acetylated α-tubulin by VPA was 
examined in VPA-sensitive, human epidermal receptor 
2 (HER2)-overexpressing SKBR3 cells. The cell growth 
inhibition of breast cancer cell lines was dependent on the 
dose and exposure time of VPA. The cell growth of HER2-
overexpressing SKBR3 cell line was inhibited by VPA to a 
much greater degree than other cell lines studied. In SKBR3 
cell line, VPA upregulated expression of p21 WAF1 and 
cleaved caspase-3 in the early phase. VPA markedly increased 
Hsp70 acetylation in a time-dependent manner but did not 
increase Hsp90 acetylation. Our data demonstrated that VPA 
inhibited cell proliferation and induced cell cycle arrest and 
apoptosis of HER2-overexpressing breast cancer cells. This 
anti-proliferation effect might be the direct function of VPA 
as an HDAC inhibitor. We propose an alternative mechanism 
whereby acetylation of Hsp70 disrupts the function of Hsp90 
and leads to downregulation of its client proteins, including 
HER2 that might be the indirect function of VPA, in the sense 
that non-histone proteins are acetylated.
Introduction
Breast cancer is one of the most common cancers in women. 
In recent years, major advances in breast cancer therapy have 
been achieved. Nevertheless, because cancer cells may present 
a number of resistance mechanisms reducing the effectiveness 
of chemotherapeutic drugs, new and more effective strategies 
for treatment and prevention are still much needed. Breast 
cancer encompasses a heterogeneous group of diseases at the 
molecular level and can be classified into at least five distinct 
subtypes by gene-expression profiling: luminal A, luminal B, 
normal breast-like, human epidermal receptor 2 (HER2), and 
basal-like. Recent studies based on neoadjuvant clinical trials 
for breast cancer suggested that chemosensitivity depends on 
its molecular subtype (1).
There is increasing evidence that epigenetic alterations, 
such as histone acetylation and promoter methylation, play 
important roles in regulation of gene expression associated 
with the cell cycle and apoptosis (2). Chromatin remodeling 
regulates gene transcription and is in turn regulated by 
two enzymes, histone acetyltransferase (HAT) and histone 
deacetylase (HDAC), that control post-translational modifica-
tions of histones. Acetylation of lysine residues on the histones 
weakens their binding to DNA and induces a change in DNA 
conformation and allows transcription factors to bind to the 
promoter regions of target genes (3,4).
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In mammalian cells, there are 18 different HDACs, which 
can be further divided into four types. HDAC 1, 2, 3, and 8 
are class I deacetylases that localize almost exclusively to 
the nucleus and are ubiquitously expressed in various human 
cell lines and tissues. HDAC 4, 5, 6, 7, 9, and 10 are class II 
deacetylases, which shuttle between the nucleus and cyto-
plasm with certain cellular signals. Class III comprises the 
conserved nicotinamide adenine dinucleotide-dependent Sir2 
family of deacetylases. HDAC11 is the only member of the 
class IV HDACs (5). Aberrant levels of HDAC activity have 
been found in a variety of human malignancies and result 
in repression of tumor-suppressor genes and promotion of 
tumorigenesis (6).
Valproic acid (VPA), which has long been used clinically 
for treatment of epilepsy and bipolar disorder without signifi-
cant toxicity, causes hyperacetylation of the N-terminal tails 
of histones H3 and H4 in vitro and in vivo and inhibits HDAC 
activity, probably by binding to the catalytic center and, 
thereby, blocking substrate access (7,8). VPA inhibits both 
class I and II HDACs, with high potency for class I HDACs (9). 
Earlier studies indicated that p21 WAF1, one of the target 
genes induced by VPA, affects differentiation and decreases 
tumor cell growth (10,11). Another report focused on the 
apoptotic activity of VPA (12). However, the detailed mecha-
nism of apoptosis induced by VPA has not been elucidated. In 
addition, recent evidence suggests that HDAC inhibitors also 
enhance the acetylation of non-histone proteins, such as p53, 
c-Jun, and α-tubulin (13-15).
Although VPA has been shown to reduce cancer prolifera-
tion to some extent, there is insufficient amount of data on its 
effect in breast cancer cells. Studies on the specificity of VPA 
against breast cancer subtypes have often yielded contrasting 
results and conflicting conclusions (16-18).
Several studies have found that inhibition of HDAC 
increases acetylation levels of the core histones as well as 
some non-histone proteins (13,19), raising the possibility that 
transcription-independent effects of HDAC inhibitors are also 
important for their anticancer activity (5). It has recently been 
reported that pan-HDAC inhibitors such as LAQ824, LBH589, 
and SAHA exert their antitumor activity by inhibition of 
HDAC6, a deacetylase of α-tubulin and heat shock protein 
(Hsp) 90 (19-21). The inhibition of HDAC6 results in acetyla-
tion of Hsp90 and disruption of its chaperone function (21-23).
Heat shock proteins (Hsps) are a group of highly conserved 
molecular chaperones which were originally identified by their 
induction in response to cellular stresses. Hsps are classified 
according to their molecular weight and in mammals five 
distinct families have been defined: Hsp100, Hsp90, Hsp70, 
Hsp60 and the small Hsps (24). As Hsp90 controls the intra-
cellular trafficking and folding of diverse cellular proteins, 
disruption of Hsp90 chaperone function will lead to the desta-
bilization and eventual degradation of Hsp90 client proteins 
and induces apoptosis (25).
HDAC6 is an unusual histone deacetylase, which harbors 
two functional catalytic domains and is localized in the 
cytoplasm (26). Some recent reports have demonstrated that 
HDAC6 is responsible for the deacetylation of acetyl-α-tubulin 
and acetyl-Hsp90 (23,27). It has been reported that the HDAC 
inhibitor FR901228 disrupts the chaperone function of Hsp90 
and induces apoptosis in human non-small cell lung cancer 
cells (13). However, as a class I HDAC inhibitor, VPA has only 
a weak effect on inhibition of HDAC6 (14,28).
It is known that Hsp70 is required for the assembly of the 
signaling protein-Hsp90 heterocomplex. Hsp90 is involved 
in two multi-chaperone complexes and promotes correct 
folding or degradation of client proteins, depending on its 
conformation. When adenosine triphosphate (ATP) is bound 
to the amino-terminal nucleotide-binding pocket, Hsp90 is 
associated with co-chaperone proteins p23 and p50Cdc37 
and directly binds to the client protein to stabilize the interac-
tions. When adenosine diphosphate (ADP) is bound, Hsp90 is 
assembled into the complex with co-chaperone proteins Hsp70 
and p60Hop. Within the complex, Hsp70 directly interacts with 
the client protein to promote ubiquitination and degradation 
(25,29). Therefore, the function of Hsp70 may indirectly affect 
the chaperone function of Hsp90. However, it is unknown 
whether VPA can influence the chaperone function of Hsp70 
and the Hsp90 in breast cancer cells. We speculate that VPA 
could enhance the acetylation of Hsp70 and Hsp90 through its 
inhibitory effect on HDAC6.
In this study, we investigated both inhibitory and pro-
apoptotic effects of VPA on breast cancer cell lines with 
various molecular subtypes. In addition, we explored whether 
VPA enhanced the acetylation of Hsp70 and Hsp90 and its 
contribution to tumor growth inhibition in the VPA-sensitive 
cell line.
Materials and methods
Materials. VPA and trichostatin A (TSA) was purchased from 
Sigma-Aldrich Co. (St. Louis, MO, USA).
Cell lines and cell culture. Two cancer cell lines derived 
from human breast cancer, estrogen receptor (ER)-positive 
and HER2-negative MCF7 cells and ER-negative and 
HER2-overexpressing SKBR3 cells were provided by the 
Cell Resource Center for Biomedical Research, Institute of 
Development, Aging and Cancer, Tohoku University. The other 
two cell lines derived from human breast cancer, ER-negative 
and HER2-negative MDA-MB-231 cells and ER-positive and 
HER2-overexpressing BT474 cells, were purchased from the 
American Type Culture Collection (Rockville, MD, USA). 
These breast cancer cells were seeded in 75-cm2 dishes 
(Becton-Dickinson, Franklin Lakes, NJ, USA) and cultured 
in 10 ml of medium at 37˚C in a humidified atmosphere of 
5% CO2. These cells were grown in DMEM (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% heat-inacti-
vated fetal bovine serum (Nichirei Bioscience Inc., Japan), 
100 IU/ml penicillin, 100 mg/ml streptomycin (Invitrogen), 
2 mM glutamine (Nissui Pharmaceutical Co., Ltd., Japan), and 
0.5 mM sodium pyruvate. Cells were grown to confluence and 
harvested by trypsinization with 0.25 mg/ml trypsin/EDTA 
solution (Invitrogen) and suspended in culture medium before 
use.
Cell growth assay. The viability of breast cancer cells treated 
with VPA was determined by 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2H-tetrazolium (MTS) assay. 
Breast cancer cells were seeded at 5x103 cells per well in 
96-well plates and incubated overnight at 37˚C. After incuba-
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tion, the supernatant was discarded and replaced with fresh 
serum-free culture medium. VPA was dissolved in phosphate-
buffered saline (PBS) and added to the cell culture medium 
at various concentrations (0-10 mM). At 24, 72, and 120 h 
after exposure to VPA, the supernatant was discarded and 
MTS solution (CellTiter 96 AQuous One Solution Reagent, 
Promega, Fitchburg, WI, USA) was added to each well and 
incubated at 37˚C for 2 h. Then, the absorbance of the solution 
was read at a wavelength of 490 nm using a microplate reader 
(Bio-Rad, Fitchburg, WI, USA). The percentage inhibition was 
determined by comparing the cell density of the drug-treated 
cells with that of untreated controls. All experiments were 
repeated at least three times. The median growth inhibition 
(GI50) corresponding to the concentration of the compound 
that inhibits 50% net cell growth was calculated for each cell 
line.
Western blotting. The mechanism of growth inhibition by 
VPA was analyzed using SKBR3 cell line, which we found to 
be the most sensitive to VPA among the four cell lines studied. 
The effects of VPA on acetylation of histone H3 and cell cycle 
regulatory and apoptosis-related proteins were analyzed by 
western blotting. Breast cancer cells were seeded at a density 
of 1x106 cells per 75-cm2 dish and cultured in 10 ml of medium 
overnight. Lysates were obtained from the cells harvested at 0, 
3, 6, 12, 24, and 48 h after incubation with 1 mM VPA, which 
corresponded approximately to the maximum level obtained 
by administering a clinical dose of VPA. Whole-cell lysates 
were prepared in denaturing SDS sample buffer and resolved 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to a PVDF membrane (ATTO Co. Ltd., Japan). 
As primary antibodies, rabbit polyclonal acetyl-histone H3 
(Lys9) antibody (1:5,000) (Cell Signaling Technology, Beverly, 
MA, USA), rabbit polyclonal histone H3 antibody (1:1,000) 
(Cell Signaling Technology), and mouse monoclonal β-actin 
antibody (1:5,000) (Sigma-Aidrich) were used. A mouse 
monoclonal p21 WAF1 (1:1,000) (Pharmingen, San Diego, 
CA, USA) was used against cell cycle regulatory proteins. 
As antibodies against apoptosis-related proteins, a rabbit 
polyclonal cleaved caspase-3 (Asp175) antibody (1:1,000) 
(Cell Signaling Technology) was used. The immunoblots 
were visualized using an ECL Plus (GE Healthcare UK, Ltd., 
Buckinghamshire, UK). Immuno-complex was detected by an 
ECL detection system (GE Healthcare). Chemiluminescent 
signal was detected by the Light-Capture system (ATTO), and 
the intensity of protein bands were quantified using the CS 
analyzer program (ATTO).
Immunoprecipitation analyses. Lysates were obtained from 
the SKBR3 cells harvested at 0, 6, 12, 24, and 48 h after incu-
bation with 1 mM VPA. Cellular extracts from ~1x106 cells 
were prepared in radio-immunoprecipitation (RIPA) buffer, 
and ~500 µg of total proteins was incubated with 2 µg of 
primary antibody at room tempreture for 60 min on a rotator. 
As primary antibodies, rabbit polyclonal Hsp70 antibody 
(Upstate Biotechnology, Lake Placid, NY, USA) and mouse 
monoclonal Hsp90 (Upstate) antibody were used. Then 20 µl 
of protein A/G-Plus-Agarose (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) was added to the mixture and incu-
bated at 4˚C for 36 h. Agarose-antibody-protein complexes 
were washed three times with lysis buffer. After discarding the 
supernatant from the final wash, the immune-complexes were 
resuspended in 50 µl of 1x electrophoresis sample buffer and 
boiled at 95˚C for 3 min. The immunoprecipitated proteins 
were separated by SDS-PAGE, and detected by using an 
ECL Plus (GE Healthcare). As primary antibodies, mouse 
monoclonal acetyl-Lysine antibody (1:1,000) (Upstate), 
Hsp70 antibody (1:1,000) and Hsp90 antibody (1:1,000) were 
used. The antibody-antigen complex was detected by western 
blotting.
Immunohistochemical examination and TUNEL assay. 
SKBR3 cells were seeded in 10-cm2 dishes and incubated over-
night at 37˚C. After incubation, the supernatant was discarded 
and replaced the cell culture medium including 1 mM VPA. 
At 48 h after exposure to VPA, the supernatant was discarded, 
and cells were fixed in 10% neutral buffered formalin and 
embedded in paraffin. The sections were stained with H&E 
and immunostained with a rabbit polyclonal cleaved caspase-3 
antibody (1:200) (Cell Signaling Technology) at 4˚C overnight. 
The sections were reacted with EnVision reagent (Dako Co., 
Japan) for visualization. For quantitative analysis, the stained 
cells were counted under x400 magnification in 6 randomly 
chosen fields representing ≥1,000 cells. The degree of apop-
tosis was evaluated using the TdT-mediated dUTP nick-end 
labeling (TUNEL) method (Apoptosis In Situ Detection kit; 
Wako, Osaka, Japan).
Results
Effects of VPA on the growth of breast cancer cell lines 
in vitro. To explore whether VPA might be a potential thera-
peutic agent against breast cancer, we investigated its effects of 
growth inhibition in human breast cancer cell lines (SKBR3, 
BT474, MDA-MB-231, and MCF7) that differed in their ER- 
or HER2-expression status. Breast cancer cells were treated 
with increasing doses of VPA for ≤5 days. The inhibition of 
cell growth in breast cancer cell lines was dependent on the 
dose and incubation time of VPA (Fig. 1). GI50 values for VPA 
(mM) in SKBR3, BT474, MDA-MB-231, and MCF7 at 72 h 
were 1.8, 3.6, 5.4 and 8.1 mM, respectively (Table Ⅰ). SKBR3 
cells, which overexpressed HER2 and were ER-negative, 
exhibited the most sensitivity towards VPA in growth inhibi-
tion. SKBR3 cell growth was inhibited by VPA at clinically 
achievable doses.
Effects of VPA on histone H3 acetylation. We evaluated the 
effects of HDAC inhibition by VPA in SKBR3 cells. The 
Table Ⅰ. Subtype and the median growth inhibition (GI50) for 
VPA of breast cancer cell lines.
 SKBR3 BT474 MDA-MB-231 MCF7
ER - + - +
HER2 ++ + - -
GI50 (mM) 1.8 3.6 5.4 8.1
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acetylation status of histone H3 in SKBR3 cells was deter-
mined during 48-h incubation with 1 mM VPA, using an 
antibody that specifically recognizes hyper-acetylated forms 
of histone H3. VPA markedly increased acetyl-histone H3 
expression by 2-fold with maximal induction at 12 h of 
incubation with VPA (Fig. 2A and B) This time frame of the 
Figure 1. Effect of VPA on the growth of breast cancer cell lines. Cell viability was assessed by MTS assay. Breast cancer cell lines [SKBR3 (A), BT474 (B), 
MDA-MB-231 (C) and MCF7 (D)] were treated with the indicated doses of VPA (0-10 mM) for 24, 48 and 120 h in serum-free medium.
Figure 2. Effect of VPA on the acetylation of histone H3 in SKBR3 cells. (A) Time courses of changes in acetyl-histone H3 and histone H3. SKBR3 cells were 
treated with 1 mM VPA, and cell lysates were harvested after time courses of ≤48 h. Western blotting was performed using a series of primary antibodies. 
(C) Time courses of changes in acetyl-histone H3 of SKBR3 cells treated with 100 nM TSA after ≤48 h. (A and C) The amount of β-actin in each sample was 
used as the loading control. (B and D) The expression levels of acetyl-histone H3 were analyzed by the Light-Capture system and then quantified using the CS 
analyzer program and reported in the histogram after normalization against β-actin, relative to the values obtained in the absence of VPA (ratio).
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maximal acetylation of histone H3 was consistent with that of 
the maximal acetylation of histone H3 treated with 100 nM 
TSA, a known, strong HDAC inhibitor (Fig. 2C and D).
Effects of VPA on cell cycle arrest. We studied differentiation 
effects of VPA by evaluating p21 WAF1 expression in SKBR3 
cells by immunoblotting. Incubation for 48 h in VPA markedly 
increased p21 WAF1 expression in SKBR3 cells in a dose-
dependent manner (Fig. 3). SKBR3 cells were treated with 
1 mM VPA ≤48 h (Fig. 4). The expression levels of p21 WAF1 
increased by ~2-3-fold during the 6-24-h incubation time in 
the presence of VPA.
Effects of VPA on apoptosis induction. To examine the apop-
tosis induction effects of VPA, we evaluated cleaved caspase-3 
expression in SKBR3 cells by immunoblotting. SKBR3 cells 
were treated with 1 mM VPA for ≤48 h (Fig. 5). The expres-
sion levels of cleaved caspase-3 increased by ~2-fold during 
the incubation times of 6-24 h in VPA. Immunohistochemical 
examination showed that the population of cleaved caspase-
3-positive SKBR3 cells was higher in VPA-treated group 
in comparison to the control group (16.6 vs. 7.4%, Fig. 6). 
Consistently, in TUNEL assay, the population of TUNEL-
positive cells was higher in VPA-treated SKBR3 cells than in 
the control group (Fig. 7).
Effects of VPA on acetylation of Hsp70 and Hsp90. We 
investigated whether VPA acetylates Hsp70 and Hsp90 in 
SKBR3 cells by immunoprecipitation and immunoblot-
ting. SKBR3 cells were treated with 1 mM VPA for ≤48 h. 
Western blotting with anti-aceyl-lysine, anti-Hsp70, and 
anti-Hsp90 antibodies after immunoprecipitation revealed 
that VPA markedly increased Hsp70 acetylation of SKBR3 
cells at 1 mM for ≤48 h in a time-dependent manner (40-fold 
increase at 48 h) (Fig. 8A and B). However, VPA did not 
induce Hsp90 acetylation at 1 mM within the time frame of 
the study (Fig. 8C).
Figure 3. Effect of VPA on the expression of p21 WAF1 in SKBR3 cells with 
the indicated doses. (A) The expression levels of p21 WAF1 were detected by 
immunoblotting on protein extracts prepared from SKBR3 cells treated with 
the indicated doses of VPA for 48 h. (B) The expression levels of p21 WAF1 
were reported in the histogram after normalization against β-actin, relative 
to the value obtained in the absence of VPA (ratio).
Figure 4. Effect of VPA on the expression of p21 WAF1 in SKBR3 cells with 
the indicated incubation times. (A) The expression levels of p21 WAF1 were 
detected by immunoblotting on protein extracts prepared from SKBR3 cells 
treated with 1 mM VPA for ≤48 h. The amount of β-actin in each sample 
was used as the loading control. (B) The expression levels of p21 WAF1 were 
reported in the histogram after normalization against β-actin, relative to the 
value obtained in the absence of VPA (ratio).
Figure 5. Effect of VPA on the expression of cleaved caspase-3 in SKBR3 
cells with the indicated incubation times. (A) The expression levels of 
cleaved caspase-3 were detected by immunoblotting on protein extracts 
prepared from SKBR3 cells treated with 1 mM VPA for ≤48 h. The 
amount of β-actin in each sample was used as the loading control. (B) The 
expression levels of cleaved caspase-3 were reported in the histogram after 
normalization against β-actin, relative to the value obtained in the absence 
of VPA (ratio).
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Figure 6. Effects of VPA on the expression of cleaved caspase-3 in SKBR3 cells. Immunohistochemical examination showed that cleaved caspase-3-positive 
SKBR3 cells treated with VPA for 48 h were increased compared with the control group (16.6% to 7.4%).
Figure 7. Effects of VPA on apoptosis in SKBR3 cells. Shrunken tumor cells showed positive reactivity in the TUNEL assay. Positive cells (arrow) in SKBR3 
cells treated with VPA for 48 h were increased compared with the control group.
Figure 8. The effects of VPA on Hsp70 and Hsp90 acetylation in SKBR3 
cells. VPA increased Hsp70, but not Hsp90, acetylation. (A and C) The RIPA 
lysates from SKBR3 cells treated with VPA for the times indicated were 
immunoprecipitated with anti-Hsp90 or anti-Hsp70 antibodies and immu-
noblotted with anti-acetyl-lysine antibody and anti-Hsp70 or anti-Hsp90 
antibodies. The levels of Hsp70 and Hsp90 in the immunoprecipitated pellet 
were used as the loading controls. (B) The expression levels of acetylated 
Hsp70 were reported in the histogram after normalization against Hsp70 in 
the absence of VPA (ratio).
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Effects of VPA on acetylation of α-tubulin. To confirm 
whether VPA has inhibitory effect on HDAC6 activity and 
leads to Hsp90 acetylation, we investigated acetylation of 
α-tubulin, which is deacetylated by HDAC6, in SKBR3 cells 
by immunoblotting. SKBR3 cells were treated with 1 mM 
VPA for ≤96 h. The expression levels of acetyl-α-tubulin were 
increased at later time (3-fold increase at 96 h) (Fig. 9). These 
data suggest that VPA has weak HDAC6 inhibitory activity.
Discussion
The present study reports that VPA has anti-proliferative 
activity in HER2-overexpressing breast cancer cells through 
cell cycle arrest and apoptosis induction at a clinically achiev-
able dose of 1 mM. Proliferation-inhibiting effect of VPA in 
HER2-overexpressing breast cancer cells might be attributable 
to dysfunction of Hsp90, which affects its client protein HER2, 
indirectly through hyper-acetylation of Hsp70.
We suggested that the diverse cellular responses to VPA 
treatment largely depend on the intrinsic characteristics of 
breast cancer cells. It is controversial whether ER-expression 
status affects the growth-inhibitory effect of HDAC inhibi-
tors. Fortunati et al (16) showed that growth of ER-positive 
breast cancer cells were suppressed by VPA in lower dose than 
ER-negative cells, while Travaglini et al (17) showed estrogen 
sensitivity had no relation with the extent of cell growth 
suppression by VPA. On the other hand, Giacinti et al (30) 
showed that ER-negative cells were more sensitive to HDAC 
inhibitor Scriptaid than ER-positive cells. Consistent with the 
results of Giacinti et al, ER-negative cell lines seem to be more 
sensitive to VPA in this study.
In our study, VPA exhibits a greater efficacy against 
HER2-overexpressing SKBR3 cells than HER2-negative 
cells, regardless of their ER-expression status. We focused 
on HER2-overexpressing SKBR3 cell line to investigate the 
mechanism of anti-proliferative activity of VPA.
Anti-proliferative activity of VPA has previously been 
reported in HER2-negative breast cancer cell lines (16-18,31-34) 
(Table Ⅱ). Huang et al (35) showed HDAC inhibitor SNDx-275 
induced strong apoptosis in HER2-overexpressing breast 
cancer cells compared with HER2-negative cells. Giacinti 
et al (30) also showed that HER2-overexpressing breast 
cancer cells were more sensitive to HDAC inhibitor Scriptaid 
than HER2-negative cells. To explore the differences among 
intrinsic subtypes of breast cancer cell lines, we studied 
the inhibition of cell growth in four different human breast 
cancer cell lines: ER-positive and HER2-negative MCF7 
cells, ER-negative and HER2-overexpressing SKBR3 cells, 
ER-negative and HER2-negative MDA-MB-231 cells, and 
ER-positive and HER2-negative BT474 cells. We confirmed 
that HER2-overexpressing breast cancer cells were more sensi-
tive to VPA treatment than HER2-negative ones. The results 
suggested that anti-proliferative mechanism of breast cancer 
cells by VPA is related to their HER2-expression status.
The cyclin-dependent kinase inhibitor p21 WAF1, which is 
involved in both the G1-S and the G2-M transition, regulates 
cell cycle progression. Fortunati et al (16) showed the anti-
proliferative effects of VPA were associated with upregulation 
of p21. In this investigation, we confirmed that VPA induced 
Figure 9. The effects of VPA on α-tubulin acetylation in SKBR3 cells. (A) The 
expression levels of acetyl-α-tubulin were detected by immunoblotting pro-
tein extracts prepared from SKBR3 cells treated with 1 mM VPA for ≤96 h. 
The amount of β-actin in each sample was used as the loading control. (B) The 
expression levels of acetyl α-tubulin were reported in the histogram after 
normalization against β-actin, relative to the value obtained in the absence 
of VPA (ratio).
Table Ⅱ. The characteristics of breast cancer cell lines treated with VPA in past reports.
Authors (Ref.) Year
Olsen et al (31) 2004 MCF7 (ER+, HER2-)
Chavez-Blanco et al (32) 2006 MCF7 (ER+, HER2-)
Hodges-Gallagher et al (33) 2007 MCF7 (ER+, HER2-)
Fortunati et al (16) 2008 MCF7 (ER+, HER2-) > ZR-75-1 (ER+, HER2+) > 
  MDA-MB-231 (ER-, HER2-) > MDA-MB435 (ER-, HER2)
Travaglini et al (17)  2009 MCF7 (ER+, HER2-) = MDA-MB-231 (ER-, HER2-)
Li et al (34) 2012 MDA-MB-231 (ER-, HER2-)
Zhang et al (18) 2012 MDA-MB-231 (ER-, HER2-)
This study 2015 SKBR3 (ER+, HER2++) > BT474  (ER-, HER2+) > 
  MDA-MB-231 (ER-, HER2-) > MCF7 (ER+, HER2-)
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cell cycle arrest with upregulation of p21 at 1 mM, in concur-
rence with the times of histone H3 acetylation.
The present study further showed that VPA induces apop-
tosis in SKBR3 cells in immunohistochemical examination 
and TUNEL assay. Caspase-3 is a critical executioner of apop-
tosis in its activated form of cleaved caspase-3. We showed that 
caspase-3 is activated in SKBR3 by VPA simultaneously as 
histone H3 acetylation. Thus VPA seemed to affect prolifera-
tion of breast cancer cells by cell cycle arrest and apoptosis 
induction.
Hsp90 is involved in two multi-chaperone complexes and 
promotes correct folding or degradation of client proteins, 
depending on its conformation (25). As class II deacetylase, 
HDAC6 is known as the deacetylase of Hsp90, and inhibiting 
the activity of HDAC6 leads to hyper-acetylation of Hsp90, 
disruption of its chaperone function, and cell apoptosis (21-23). 
VPA is known to have a weak inhibitory effect on HDAC6, 
and we could not directly observe VPA-induced acetylation 
of Hsp90 in SKBR3 cells. However, we showed that VPA had 
acetylation effect against α-tubulin. Considering that HDAC6 
is the only known deacetylase of α-tubulin, the increased 
acetylation of α-tubulin indicates that VPA can partially 
inhibit HDAC6 activity. HDAC inhibition by VPA might be 
insufficient to acetylate Hsp90. On the other hand, we showed 
that VPA could acetylate Hsp70. It is known that Hsp70 is 
required for the assembly of the signaling protein-Hsp90 
heterocomplex.
We thought VPA may disrupt the function of Hsp90 indi-
rectly through hyper-acetylation of Hsp70. Wang et al (36) 
showed that FK228, a class I HDAC inhibitor, blocked Hsp90 
chaperone function in K562 CML cells via hyper-acetylation 
of Hsp70. Fuino et al (37) showed that LAQ824, a hydroxamic 
acid analogue HDAC inhibitor, induced acetylation of Hsp90, 
and reduced its binding to ATP. In SKBR3 and BT474 cells, 
treatment with LAQ824 shifted the chaperone association of 
HER2 from Hsp90 to Hsp70, which efficiently ubiquitinates 
and downregulates HER2. Scott et al (38) showed that treat-
ment with TSA, a strong HDAC inhibitor, in SKBR3 and 
BT474 cells produced the expected marked decline in their 
endogenous HER2 protein levels. Meng et al (39) showed  that 
treatment with carbamazepine (CBZ), an anti-epileptic drug 
that acts as an HDAC inhibitor in SKBR3 cells, produced 
a marked decline in their HER2 protein levels. In the same 
study, CBZ was shown to synergize with trastuzumab 
inhibiting breast cancer cell proliferation more strongly than 
CBZ or trastuzumab alone. Therefore, VPA may synergize 
with trastuzumab to inhibit HER2-overexpressing breast 
cancer cell proliferation more strongly. The fact that HER2-
overexpressing breast cancer cells were more sensitive to VPA 
than HER2-negative cells seems to be associated with the 
role of HER2 as a client protein of Hsp90. We speculate VPA 
may disrupt the function of Hsp90 indirectly through hyper-
acetylation of Hsp70 and downregulation of HER2 expression, 
thus suppressing cell growth.
Our results showed that the class I and II HDAC inhibitor 
VPA preferably inhibited cell proliferation and induced cell 
cycle arrest and apoptosis of HER2-overexpressing breast 
cancer cells. This effect might be a direct function of VPA as 
an HDAC inhibitor. Moreover, we propose another mechanism 
of anti-proliferation that might be related to its non-histone 
acetylation effect by indirectly disrupting Hsp90 function 
via acetylation of Hsp70 and leading to downregulation of 
its client proteins, including HER2. We showed that, in addi-
tion to the direct function of VPA in histone acetylation that 
results in cell cycle arrest or apoptosis, its indirect function 
of acetylation of non-histone proteins could result in the 
anti-proliferative activity of VPA. To confirm this hypothesis, 
further study is required.
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